SEC Comment Letter 0000000000-24-000679 to Evaxion A/S (EVAX)
Evaxion A/S
Date: Jan. 18, 2024 · CIK: 0001828253 · Accession: 0000000000-24-000679
AI Filing Summary & Sentiment
File numbers found in text: 333-276505
Letter
United States securities and exchange commission logo January 18, 2024 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 Hørsholm Denmark Re:Evaxion Biotech A/S Registration Statement on Form F-1 Filed January 12, 2024 File No. 333-276505 Dear Christian Kanstrup: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael D. Baird
Show Raw Text
United States securities and exchange commission logo
January 18, 2024
Christian Kanstrup
Chief Executive Officer
Evaxion Biotech A/S
Dr. Neergaards Vej 5F
2970 Hørsholm
Denmark
Re:Evaxion Biotech A/S
Registration Statement on Form F-1
Filed January 12, 2024
File No. 333-276505
Dear Christian Kanstrup:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael D. Baird